Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MDXG 
MiMedx Group Inc (MDXG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/07/2025: MDXG (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.2
1 Year Target Price $12.2
| 5 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.87% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.07B USD | Price to earnings Ratio 34.48 | 1Y Target Price 12.2 |
Price to earnings Ratio 34.48 | 1Y Target Price 12.2 | ||
Volume (30-day avg) 5 | Beta 1.79 | 52 Weeks Range 5.47 - 10.14 | Updated Date 08/7/2025 |
52 Weeks Range 5.47 - 10.14 | Updated Date 08/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-07-29 | When Before Market | Estimate 0.054 | Actual 0.1 |
Profitability
Profit Margin 8.84% | Operating Margin (TTM) 12.55% |
Management Effectiveness
Return on Assets (TTM) 10.37% | Return on Equity (TTM) 16.61% |
Valuation
Trailing PE 34.48 | Forward PE 19.53 | Enterprise Value 970818171 | Price to Sales(TTM) 2.94 |
Enterprise Value 970818171 | Price to Sales(TTM) 2.94 | ||
Enterprise Value to Revenue 2.67 | Enterprise Value to EBITDA 18.41 | Shares Outstanding 147959008 | Shares Floating 109563948 |
Shares Outstanding 147959008 | Shares Floating 109563948 | ||
Percent Insiders 1.7 | Percent Institutions 70.21 |
Upturn AI SWOT
MiMedx Group Inc
Company Overview
History and Background
MiMedx Group Inc. was founded in 2008. It focuses on developing and marketing regenerative biomaterial products and therapies derived from human placental tissue. The company experienced significant growth followed by accounting controversies, resulting in a restatement of financials and changes in leadership.
Core Business Areas
- Wound Care: This segment offers advanced wound care products derived from placental tissue for chronic and acute wounds.
- Surgical & Sports Medicine: This segment provides regenerative products used in surgical procedures and sports medicine applications, focusing on tissue repair and regeneration.
Leadership and Structure
The company has a board of directors overseeing executive management. The current CEO is Joseph H. Ciavarella. The organizational structure includes departments for R&D, sales and marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- EpiFix: A dehydrated human amnion/chorion membrane (dHACM) allograft used for wound healing. Competitors include Integra LifeSciences (IART), Organogenesis (ORGO), and Smith & Nephew (SNN). Specific market share data is difficult to pinpoint precisely due to varying market definitions and limited disclosures, but EpiFix is a significant player in the advanced wound care market.
- AmnioFix: A dHACM allograft used in surgical and sports medicine applications. Competitors include Osiris Therapeutics (acquired by Smith & Nephew), and other companies offering biological scaffolds for tissue repair. Similar to EpiFix, specific market share data is challenging to obtain, but AmnioFix holds a prominent position in its target market.
Market Dynamics
Industry Overview
The regenerative medicine and advanced wound care markets are experiencing growth driven by aging populations, increasing prevalence of chronic diseases (e.g., diabetes), and advancements in biomaterial technologies.
Positioning
MiMedx aims to be a leader in regenerative biomaterials derived from placental tissue. Their competitive advantage lies in their proprietary processing techniques and established clinical evidence.
Total Addressable Market (TAM)
The total addressable market for wound care and surgical biologics is estimated to be in the billions of dollars globally. MiMedx is positioned to capture a portion of this market through its existing product portfolio and ongoing R&D efforts.
Upturn SWOT Analysis
Strengths
- Proprietary processing technology
- Established clinical evidence for products
- Strong brand recognition within specific segments
- Experienced leadership team (current)
Weaknesses
- Past accounting controversies and legal challenges
- Reliance on a limited number of key products
- Pricing pressure from competitors
- Potential regulatory hurdles
Opportunities
- Expansion into new geographic markets
- Development of new product applications
- Strategic partnerships and acquisitions
- Increasing adoption of regenerative medicine therapies
Threats
- Intense competition in the advanced wound care market
- Changes in reimbursement policies
- Potential product liability claims
- Emergence of disruptive technologies
Competitors and Market Share
Key Competitors
- IART
- ORGO
- SNN
Competitive Landscape
MiMedx faces strong competition from established players in the advanced wound care and surgical biologics markets. Their success depends on differentiating their products through clinical data, pricing strategies, and customer service.
Major Acquisitions
None
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: No major acquisitions in recent years.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was significant prior to the accounting restatement, followed by a period of recovery and rebuilding.
Future Projections: Future growth projections depend on successful execution of their strategic plan and market conditions. Analyst estimates vary.
Recent Initiatives: Recent initiatives include new product launches, expansion of the sales force, and efforts to improve operational efficiency and compliance.
Summary
MiMedx is a regenerative medicine company focused on placental-derived biomaterials. The company has had challenges but is now focusing on sustainable growth. Their proprietary technologies and strong clinical evidence are key strengths. Future performance depends on successfully navigating the competitive landscape and executing their strategic plan.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Market Reports
- Analyst Estimates
- Company Website
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MiMedx Group Inc
Exchange NASDAQ | Headquaters Marietta, GA, United States | ||
IPO Launch date 2007-08-22 | CEO & Director Mr. Joseph H. Capper | ||
Sector Healthcare | Industry Biotechnology | Full time employees 837 | Website https://www.mimedx.com |
Full time employees 837 | Website https://www.mimedx.com | ||
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.